Investigative Summary: Findings of Misconduct by a then Senior Official with the Drug Enforcement Administration for Misuse of Official Position Related to Giving Preferential Treatment to a Pharmaceutical Company, and Related Misconduct
- NARA ID
- investigative-summary-findings-misconduct-then-senior-official-drug-enforcement
- Source
- oig-doj
- Collection
- DOJ OIG — Drug Enforcement Administration
- Agency
- U.S. DOJ Office of the Inspector General
- Classification
- Investigation
- Released
- 2021-12-02
- Slug
- doj-oig-investigative-summary-findings-misconduct-then-senior-official-drug-enforcement
- Indexed
- 2026-04-27 05:02:45
More from DOJ OIG — Drug Enforcement Administration
- Summary of OIG Investigative Findings Regarding the Detention by the Drug Enforcement Administration of Daniel Chong
- Memorandum for the Deputy Attorney General: Recommendation for the Drug Enforcement Administration to Review whether its Field Offices are Engaging in Unlawful Fundraising on Behalf of the Drug Enforcement Administration Survivors Benefit Fund
- Audit of the Drug Enforcement Administration’s Laboratory Information Management System Support Contracts
- Audit of the Drug Enforcement Administration's Spider Core System Pursuant to the Federal Information Security Modernization Act of 2014, Fiscal Year 2021
- Audit of the Drug Enforcement Administration's Income-Generating, Undercover Operations
- Review of the Drug Enforcement Administration's Regulatory and Enforcement Efforts to Control the Diversion of Opioids
Browse all 56 documents in DOJ OIG — Drug Enforcement Administration →
About the DOJ OIG — Drug Enforcement Administration collection
U.S. DOJ Office of the Inspector General reports (audits, investigations, evaluations, and reviews) concerning Drug Enforcement Administration.